Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > October 6, 2025
Daily News
October 6, 2025
- Inside Eylea - 1: Patent Issues Behind Differences in Biosimilar Indications for AMD and DME
October 6, 2025
- Japan to Allow Vaccine Strain Changes Under PACMP Framework
October 6, 2025
- NPhA Urges Pharmacies to Provide Accurate Info on Acetaminophen Use during Pregnancy
October 6, 2025
- Takeda Pulls Plug on Cell Therapy Work after Strategy Review
October 6, 2025
- Japan Patient Group Calls for Dupixent Approval in Ichthyosis
October 6, 2025
- Japan Health Minister Mum on NIP Use of RSV Preventives for Children
October 6, 2025
- LEO Pharma Begins Promotional Activities for Spevigo in Japan
October 6, 2025
- Sanofi Files ITP Drug Rilzabrutinib in Japan
October 6, 2025
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…